Abstract
Waldenström's Macroglobulinemia (WM) is a low-grade non-Hodgkin lymphoma with an incidence of approximately three per million-persons per year, classifying it as a rare cancer. Rare cancers are inherently difficult to study in large clinical trials, resulting in paucity of well-founded evidence. As such, the diverse manifestations of disease and response to different treatments, including quality of life (QoL) outcomes, are less well-understood than in more common cancers. Patient-derived data can facilitate generation of large datasets to help address this gap.